Ivan Nestorov
Research Subjects
Ivan Nestorov has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Alain Munafo
Geneva, Switzerland
1 shared publicationJennifer Visich
ZymoGenetics, Seattle, Washington, and Merck Serono International S.A. (an affiliate of Merck KGaA, Darmstadt, Germany)
1 shared publicationOrestis Papasouliotis
Geneva, Switzerland
1 shared publication
Latest Publications
- 1 April 2008
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 48 (4) , 406-417
Pharmacokinetics and Biological Activity of Atacicept in Patients With Rheumatoid Arthritis
Atacicept is a recombinant fusion protein containing the extracellular ligand‐binding portion of the transmembrane activator and CAML interactor (TACI, CD267) receptor and inhibits B lymphocyte stimulator (BLyS, CD257) and a proliferation‐inducing ligand (APRIL, CD256), both potent stimulators of B cell maturation, proliferation, and survival. Atacicept pharmacokinetics and pharmacodynamics were assessed in a double‐blind, placebo‐controlled, phase I study in patients with active, moderate to severe rheumatoid arthritis receiving atacicept either as a single subcutaneous or repeated, every other week dose. Pharmacokinetic profiles were determined by measuring serum concentrations of free atacicept and its complex with BLyS. Nonspecific immunoglobulin (Ig)M, IgG, and IgA; IgM‐RF (rheumatoid factor), IgG‐RF, and IgA‐RF antibody levels; and B cell profiles provided markers of biological activity. Pharmacokinetic, biological activity, and relationships between atacicept dose and Ig antibody response were evaluated. Pharmacokinetic profiles of atacicept were nonlinear, influenced by saturable binding with its ligands, but were consistent and predictable. Atacicept treatment reduced Ig and RF serum concentration. IgM antibody levels were most sensitive to atacicept, followed by IgA and IgG, underlining the biological activity of atacicept in patients with rheumatoid arthritis. These findings can be used to explore dosing regimen design scenarios in future studies.
- 1 April 2008
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 48 (4) , 406-417
Pharmacokinetics and Biological Activity of Atacicept in Patients With Rheumatoid Arthritis
Atacicept is a recombinant fusion protein containing the extracellular ligand‐binding portion of the transmembrane activator and CAML interactor (TACI, CD267) receptor and inhibits B lymphocyte stimulator (BLyS, CD257) and a proliferation‐inducing ligand (APRIL, CD256), both potent stimulators of B cell maturation, proliferation, and survival. Atacicept pharmacokinetics and pharmacodynamics were assessed in a double‐blind, placebo‐controlled, phase I study in patients with active, moderate to severe rheumatoid arthritis receiving atacicept either as a single subcutaneous or repeated, every other week dose. Pharmacokinetic profiles were determined by measuring serum concentrations of free atacicept and its complex with BLyS. Nonspecific immunoglobulin (Ig)M, IgG, and IgA; IgM‐RF (rheumatoid factor), IgG‐RF, and IgA‐RF antibody levels; and B cell profiles provided markers of biological activity. Pharmacokinetic, biological activity, and relationships between atacicept dose and Ig antibody response were evaluated. Pharmacokinetic profiles of atacicept were nonlinear, influenced by saturable binding with its ligands, but were consistent and predictable. Atacicept treatment reduced Ig and RF serum concentration. IgM antibody levels were most sensitive to atacicept, followed by IgA and IgG, underlining the biological activity of atacicept in patients with rheumatoid arthritis. These findings can be used to explore dosing regimen design scenarios in future studies.
- 11 April 2007
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 3 (2) , 235-249
Whole-body physiologically based pharmacokinetic models
This review summarizes the most recent developments in and applications of physiologically based pharmacokinetic (PBPK) modeling methodology originating from both the pharmaceutical and environmental toxicology areas. It focuses on works published in the last 5 years, although older seminal papers have also been referenced. After a brief introduction to the field and several essential definitions, the main body of the text is structured to follow the major steps of a typical PBPK modeling exercise. Various applications of the methodology are briefly described. The major future trends and perspectives are outlined. The main conclusion from the review of the available literature is that PBPK modeling, despite its obvious potential and recent incremental developments, has not taken the place it deserves, especially in pharmaceutical and drug development sciences.
- 11 April 2007
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 3 (2) , 235-249
Whole-body physiologically based pharmacokinetic models
This review summarizes the most recent developments in and applications of physiologically based pharmacokinetic (PBPK) modeling methodology originating from both the pharmaceutical and environmental toxicology areas. It focuses on works published in the last 5 years, although older seminal papers have also been referenced. After a brief introduction to the field and several essential definitions, the main body of the text is structured to follow the major steps of a typical PBPK modeling exercise. Various applications of the methodology are briefly described. The major future trends and perspectives are outlined. The main conclusion from the review of the available literature is that PBPK modeling, despite its obvious potential and recent incremental developments, has not taken the place it deserves, especially in pharmaceutical and drug development sciences.
- 1 April 2005
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 34 (5) , 12-18
Clinical pharmacokinetics of TNF antagonists: How do they differ?
- 1 April 2005
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 34 (5) , 12-18
Clinical pharmacokinetics of TNF antagonists: How do they differ?